Open AccessSemiquantitative Analysis of Apolipoprotein A ‐ I Modified by Advanced Glycation End Products in Diabetes Mellitus
Author(s) -
Kurosaki Yoshifumi,
Tsukushi Tomoaki,
Munekata Shinichi,
Akahoshi Tohru,
Moriya Tatsumi,
Ogawa Zensuke
Publication year - 2013
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.21591
Subject(s) - medicine , endocrinology , insulin resistance , diabetes mellitus , glycation , dyslipidemia , apolipoprotein b , methylglyoxal , glycated hemoglobin , insulin , lipoprotein , chemistry , cholesterol , enzyme , biochemistry , type 2 diabetes
Background Apolipoprotein A ‐ I ( Apo A ‐ I ), the major component of high‐density lipoprotein ( HDL ), is modified by reactive α‐oxoaldehydes, such as methylglyoxal ( MG ) and glycolaldehyde ( GA ), and these modifications affect the function of Apo A ‐ I . GA ‐ and MG ‐modified Apo A ‐ I serum levels were semiquantitatively evaluated in diabetic patients to elucidate the association of each protein with diabetes and to determine its appropriateness as a serum marker of diabetes. Methods We enrolled 44 subjects in this study (diabetic subjects, n = 24; nondiabetic subjects, n = 20). GA ‐ and MG ‐modified Apo A ‐ I levels in serum were determined by sandwich enzyme‐linked immunosorbent assay ( ELISA ) by using anti‐ GA or anti‐ MG antibody and anti‐ Apo A ‐ I antibody. Results The GA ‐modified Apo A ‐ I levels did not significantly differ between the diabetic and nondiabetic subjects (1.00 ± 0.38 vs. 0.96 ± 0.22). However, the MG ‐modified Apo A ‐ I levels in the diabetic subjects were significantly higher than those in the nondiabetic subjects (1.33 ± 0.52 vs. 0.90 ± 0.20). In addition, MG ‐modified Apo A ‐ I levels correlated with the glycated hemoglobin ( H b A 1c) levels, HDL ‐cholesterol levels, and the homeostasis model assessments of insulin resistance, which are indicators of insulin resistance. Conclusion The MG ‐modified Apo A ‐ I level may be an indicator of diabetic dyslipidemia and insulin resistance.